Methylphenidate Explained

Watchedfields:changed
Verifiedrevid:464371569
Width:200
Width2:225
Tradename:Ritalin, Concerta, others
Dailymedid:Methylphenidate
Pregnancy Au:D
Dependency Liability:High
Addiction Liability:High[1]
Routes Of Administration:Insufflation, intravenous, oral, rectal, sublingual, transdermal
Class:Central nervous system stimulant & norepinephrine–dopamine reuptake inhibitor
Atc Prefix:N06
Atc Suffix:BA04
Legal Au:S8
Legal Br:A3
Legal Br Comment:[2]
Legal Ca:Schedule III
Legal Ca Comment:[3] [4] [5]
Legal De:Anlage III
Legal Uk:Class B
Legal Nz:Class B
Legal Us:Schedule II
Legal Us Comment:[6] [7] [8] [9]
Legal Un:P II
Bioavailability:Insufflation: approx. 70%Oral: approx. 30% (range: 11–52%)
Protein Bound:10–33%
Metabolism:Liver (80%) mostly CES1-mediated
Elimination Half-Life:2–3 hours
Excretion:Urine (90%)
Cas Number:20748-11-2
Pubchem:4158
Iuphar Ligand:7236
Drugbank:DB00422
Chemspiderid:4015
Unii:207ZZ9QZ49
Kegg:D04999
Chebi:6887
Chembl:796
Synonyms:MPH
Iupac Name:Methyl phenyl(piperidin-2-yl)acetate
C:14
H:19
N:1
O:2
Smiles:COC(=O)C(c1ccccc1)C1CCCCN1
Stdinchi:1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3
Stdinchikey:DUGOZIWVEXMGBE-UHFFFAOYSA-N
Melting Point:74
Melting Notes:[10]
Boiling Point:136

Methylphenidate, sold under the brand names Ritalin and Concerta among others, is a potent central nervous system (CNS) stimulant used medically to treat attention deficit hyperactivity disorder (ADHD) and, to a lesser extent, narcolepsy. It is a primary medication for ADHD (e.g. in the UK[11]); it may be taken by mouth or applied to the skin, and different formulations have varying durations of effect.[12] For ADHD, the effectiveness of methylphenidate is comparable to atomoxetine[13] [14] [15] [16] but modestly lower than amphetamines,[17] [18] [19] [20] alleviating the executive functioning deficits of sustained attention, inhibition, working memory, reaction time[21] and emotional self-regulation.[22] [23]

Common adverse reactions of methylphenidate include euphoria, dilated pupils, tachycardia, palpitations, headache, insomnia, anxiety, hyperhidrosis, weight loss, decreased appetite, dry mouth, nausea, and abdominal pain. Withdrawal symptoms may include chills, depression, drowsiness, dysphoria, exhaustion, headache, irritability, lethargy, nightmares, restlessness, suicidal thoughts, and weakness.[12]

Methylphenidate is believed to work by blocking the reuptake of dopamine and norepinephrine by neurons.[24] [25] It is a central nervous system (CNS) stimulant of the phenethylamine and piperidine classes. It is available as a generic medication.[26] In 2021, it was the 43rd most commonly prescribed medication in the United States, with more than 15.2million prescriptions.[27] [28]

Etymology

The word methylphenidate is a portmanteau of the chemical name, Methyl-2-phenyl-2-(piperidin-2-yl) acetate.

The name "Ritalin" derives from Marguerite "Rita" Panizzon, the wife of Leandro Panizzon, who first synthesized the drug in 1944. Rita was the first person to take methylphenidate, and described its effects to her husband.[29]

Uses

Methylphenidate is most commonly used to treat ADHD and narcolepsy.[30]

Attention deficit hyperactivity disorder

Methylphenidate is used for the treatment of attention deficit hyperactivity disorder (ADHD).[31] The dosage may vary and is titrated to effect, with some guidelines recommending initial treatment with a low dose.[32] Methylphenidate is available in both immediate-release and extended-release (XR) formulations to provide a sustained release of the drug.[33] [34] Methylphenidate is not approved for children under six years of age.[35] [36]

The International Consensus Statement on ADHD shows that the results from systematic reviews, meta-analyses and large scale studies are clear: methylphenidate is safe and efficacious, but also among the most efficacious drugs in all of medicine; treatment in the long-term significantly reduces or eliminates the elevated risks for obesity, accidental injuries, traumatic brain injury, substance abuse, cigarette smoking, educational underachievement, bone fractures, sexually transmitted infections, depression, suicide, criminal activity, teenage pregnancy, vehicle crashes, burn injuries and overall-cause mortality.[37]

One committee from the World Health Organization (WHO) responsible for the World Health Organization Essential Medicines List rejected an application in 2019, and a second application endorsed by 51 professional medical groups in 2021, for methylphenidate's inclusion due to uncertainty about its efficacy and safety.[38] [39] However, in November 2023, the WHO Mental Health Gap Action Programme Guidelines for mental, neurological, and substance use disorders makes a clear recommendation that methylphenidate should be considered for children aged 6 years and older who have ADHD, noting specifically that, "methylphenidate treatment shows substantial effects on symptom reduction",[40] in addition to other WHO publications.[41] In 2024, the European Society for Child and Adolescent Psychiatry (ESCAP) and the American Academy of Paediatrics (ACP) endorsed the inclusion of methylphenidate in the WHO EML.[42] [43]

Safety and efficacy data have been reviewed extensively by medical regulators (e.g., the US Food and Drug Administration and the European Medicines Agency), the developers of evidence-based national guidelines (e.g., the UK National Institute for Health and Care Excellence and the American Academy of Pediatrics), and government agencies who have endorsed these guidelines (e.g., the Australian National Health and Medical Research Council). These professional groups unanimously conclude, based on the scientific evidence, that methylphenidate is safe and effective and should be considered as a first-line treatment for ADHD.

Since ADHD diagnosis has increased around the world, methylphenidate may be misused as a "study drug" by some populations, which may be harmful.[44] This also applies to people who may be experiencing a different issue and are misdiagnosed with ADHD. People in this category can then experience negative side-effects of the drug, which worsen their condition.

Long-term meta-analyses and systematic reviews show that the medications used to treat ADHD are not associated with observed deficits in brain structure, but with improved brain development and functioning, most prominently in inferior frontal and striatal regions. The most comprehensive meta-analysis available (19 studies with over 3.9 million participants) found "no statistically significant association between ADHD medications [including methylphenidate] and the risk of cardiovascular event among children and adolescents, young and middle-aged adults, or older adults";[45] as do other systematic reviews and meta-analyses.[46] [47] [48]

Narcolepsy

Narcolepsy, a chronic sleep disorder characterized by overwhelming daytime drowsiness and uncontrollable sleep, is treated primarily with stimulants. Methylphenidate is considered effective in increasing wakefulness, vigilance, and performance.[49] Methylphenidate improves measures of somnolence on standardized tests, such as the Multiple Sleep Latency Test (MSLT), but performance does not improve to levels comparable to healthy people.[50]

Other medical uses

Methylphenidate may also be prescribed for off-label use in treatment-resistant cases of bipolar disorder and major depressive disorder.[51] It can also improve depression in several groups, including stroke, cancer, and HIV-positive patients.[52] There is weak evidence in favor of methylphenidate's effectiveness for depression,[53] including providing additional benefit in combination with antidepressants.[54] In individuals with terminal cancer, methylphenidate can be used to counteract opioid-induced somnolence, to increase the analgesic effects of opioids, to treat depression, and to improve cognitive function.[55] A 2021 systematic review and meta-analysis found that all studies on geriatric depression reported positive results of methylphenidate use; the review recommended short-term use in combination with citalopram.[56] A 2018 review found low-quality evidence supporting its use to treat apathy as seen in Alzheimer's disease, in addition to slight benefits for cognition and cognitive performance.[57]

Enhancing performance

Methylphenidate's efficacy as an athletic performance enhancer, cognitive enhancer, aphrodisiac, and euphoriant is supported by research.[58] [59] [60] [61] [62] [63] [64] [65] [66] However, the manner in which methylphenidate is used for these purposes (high dosages, alternate routes of administration, during sleep deprivation, etc.) can result in severe unintended side effects.[67] [68] A 2015 review found that therapeutic doses of amphetamine and methylphenidate result in modest improvements in cognition, including working memory, episodic memory, and inhibitory control, in normal healthy adults;[69] [70] the cognition-enhancing effects of these drugs are known to occur through the indirect activation of both dopamine receptor D1 and adrenoceptor α2 in the prefrontal cortex.[69] Methylphenidate and other ADHD stimulants also improve task saliency and increase arousal.[71] Stimulants such as amphetamine and methylphenidate can improve performance on difficult and boring tasks,[72] [71] [73] and are used by some students as a study and test-taking aid.[44] [74] Based upon studies of self-reported illicit stimulant use, performance-enhancing use rather than use as a recreational drug, is the primary reason that students use stimulants.[75]

Excessive doses of methylphenidate, above the therapeutic range, can interfere with working memory and cognitive control.[72] [71] Like amphetamine and bupropion, methylphenidate increases stamina and endurance in humans primarily through reuptake inhibition of dopamine in the central nervous system.[76] Similar to the loss of cognitive enhancement when using large amounts, large doses of methylphenidate can induce side effects that impair athletic performance, such as rhabdomyolysis and hyperthermia. While literature suggests it might improve cognition, most authors agree that using the drug as a study aid when an ADHD diagnosis is not present does not actually improve GPA.[44] Moreover, it has been suggested that students who use the drug for studying may be self-medicating for potentially deeper underlying issues.[44]

Contraindications

Methylphenidate is contraindicated for individuals with agitation, tics, glaucoma, heart defects or a hypersensitivity to any ingredients contained in methylphenidate pharmaceuticals.

Pregnant women are advised to only use the medication if the benefits outweigh the potential risks.[77] Not enough human studies have been conducted to conclusively demonstrate an effect of methylphenidate on fetal development.[78] In 2018, a review concluded that it has not been teratogenic in rats and rabbits, and that it "is not a major human teratogen".[79]

Adverse effects

The most common side effects associated with methylphenidate (in standard and extended-release formulations) are appetite loss, dry mouth, anxiety/nervousness, nausea, and insomnia.[80] Gastrointestinal adverse effects may include abdominal pain and weight loss. Nervous system adverse effects may include akathisia (agitation/restlessness), irritability, dyskinesia (tics), lethargy (drowsiness/fatigue), and dizziness. Cardiac adverse effects may include palpitations, changes in blood pressure, and heart rate (typically mild), and tachycardia (rapid heart rate).[81] Ophthalmologic adverse effects may include blurred vision caused by pupil dilatation and dry eyes, with less frequent reports of diplopia and mydriasis.[82]

Results from a 2024 systematic review showed that methylphenidate significantly improves ADHD symptoms and broadband measures but can cause appetite suppression and other adverse events in children and adolescents.[83] Smokers with ADHD who take methylphenidate may increase their nicotine dependence, and smoke more often than before they began using methylphenidate, with increased nicotine cravings and an average increase of 1.3 cigarettes per day.[84]

There is some evidence of mild reductions in height with prolonged treatment in children.[85] This has been estimated at 11NaN1 or less per year during the first three years with a total decrease of 31NaN1 over 10 years.[86] [87]

Hypersensitivity (including skin rash, urticaria, and fever) is sometimes reported when using transdermal methylphenidate. The Daytrana patch has a much higher rate of skin reactions than oral methylphenidate.[88]

Methylphenidate can worsen psychosis in people who are psychotic, and in very rare cases it has been associated with the emergence of new psychotic symptoms.[89] It should be used with extreme caution in people with bipolar disorder due to the potential induction of mania or hypomania.[90] There have been very rare reports of suicidal ideation, but some authors claim that evidence does not support a link.[85] Logorrhea is occasionally reported and visual hallucinations are very rarely reported.[91] Priapism is a very rare adverse event that can be potentially serious.[92]

U.S. Food and Drug Administration-commissioned studies in 2011 indicate that in children, young adults, and adults, there is no association between serious adverse cardiovascular events (sudden death, heart attack, and stroke) and the medical use of methylphenidate or other ADHD stimulants.[93]

Because some adverse effects may only emerge during chronic use of methylphenidate, a constant watch for adverse effects is recommended.[94]

A 2018 Cochrane review found that methylphenidate might be associated with serious side effects such as heart problems, psychosis, and death. The certainty of the evidence was stated as very low.

The same review found tentative evidence that it may cause both serious and non-serious adverse effects in children.[95]

Overdose

The symptoms of a moderate acute overdose on methylphenidate primarily arise from central nervous system overstimulation; these symptoms include: vomiting, nausea, agitation, tremors, hyperreflexia, muscle twitching, euphoria, confusion, hallucinations, delirium, hyperthermia, sweating, flushing, headache, tachycardia, heart palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes.[9] A severe overdose may involve symptoms such as hyperpyrexia, sympathomimetic toxidrome, convulsions, paranoia, stereotypy (a repetitive movement disorder), rhabdomyolysis, coma, and circulatory collapse.[9] [96] [97] A methylphenidate overdose is rarely fatal with appropriate care.[97] Following injection of methylphenidate tablets into an artery, severe toxic reactions involving abscess formation and necrosis have been reported.[98]

Treatment of a methylphenidate overdose typically involves the administration of benzodiazepines, with antipsychotics, α-adrenoceptor agonists and propofol serving as second-line therapies.[97]

Addiction and dependence

Methylphenidate is a stimulant with an addiction liability and dependence liability similar to amphetamine. It has moderate liability among addictive drugs;[99] accordingly, addiction and psychological dependence are possible and likely when methylphenidate is used at high doses as a recreational drug. When used above the medical dose range, stimulants are associated with the development of stimulant psychosis.[100]

Biomolecular mechanisms

Methylphenidate has the potential to induce euphoria due to its pharmacodynamic effect (i.e., dopamine reuptake inhibition) in the brain's reward system. At therapeutic doses, ADHD stimulants do not sufficiently activate the reward system; consequently, when taken as directed in doses that are commonly prescribed for the treatment of ADHD, methylphenidate use lacks the capacity to cause an addiction.[101]

Interactions

Methylphenidate may inhibit the metabolism of vitamin K anticoagulants, certain anticonvulsants, and some antidepressants (tricyclic antidepressants, and selective serotonin reuptake inhibitors). Concomitant administration may require dose adjustments, possibly assisted by monitoring of plasma drug concentrations.[8] There are several case reports of methylphenidate inducing serotonin syndrome with concomitant administration of antidepressants.[102] [103] [104] [105]

When methylphenidate is coingested with ethanol, a metabolite called ethylphenidate is formed via hepatic transesterification,[106] [107] not unlike the hepatic formation of cocaethylene from cocaine and ethanol. The reduced potency of ethylphenidate and its minor formation means it does not contribute to the pharmacological profile at therapeutic doses and even in overdose cases ethylphenidate concentrations remain negligible.[108] [107]

Coingestion of alcohol also increases the blood plasma levels of d-methylphenidate by up to 40%.[109]

Liver toxicity from methylphenidate is extremely rare, but limited evidence suggests that intake of β-adrenergic agonists with methylphenidate may increase the risk of liver toxicity.[110]

Pharmacology

Pharmacodynamics

Binding profile[111] [112] [113]
Neurotransmitter
transporter		Measure
(units)
DATKi 1211612250
IC50 20231600
NETKi (nM)788206>10000
IC50 (nM)5139980
SERTKi (nM)>10000>10000>6700
IC50 (nM)—| >10000| >10000|-! GPCR! Measure
(units)! ! ! |-|rowspan="2"| 5-HT1A| Ki | 5000| 3400| >10000|-| IC50 | 10000| 6800| >10000|-|rowspan="2"| 5-HT2B| Ki (nM)| >10000| 4700| >10000|-| IC50 (nM)| >10000| 4900| >10000|}Methylphenidate acts primarily as a strong norepinephrine–dopamine reuptake inhibitor (NDRI). It is a benzylpiperidine and phenethylamine derivative which also shares part of its basic structure with catecholamines.

Methylphenidate is a psychostimulant and increases the activity of the central nervous system through inhibition on reuptake of the neurotransmitters norepinephrine and dopamine. As models of ADHD suggest, it is associated with functional impairments in some of the brain's neurotransmitter systems, particularly those involving dopamine in the mesocortical and mesolimbic pathways and norepinephrine in the prefrontal cortex and locus coeruleus. Psychostimulants like methylphenidate and amphetamine may be effective in treating ADHD because they increase neurotransmitter activity in these systems. When reuptake of those neurotransmitters is halted, its concentration and effects in the synapse increase and last longer, respectively. Therefore, methylphenidate is called a norepinephrine–dopamine reuptake inhibitor. By increasing the effects of norepinephrine and dopamine, methylphenidate increases the activity of the central nervous system and produces effects such as increased alertness, reduced fatigue, and improved attention.[114] [115]

Methylphenidate is most active at modulating levels of dopamine (DA) and to a lesser extent norepinephrine (NE).[116] Methylphenidate binds to and blocks dopamine transporters (DAT) and norepinephrine transporters (NET).[117] Variability exists between DAT blockade, and extracellular dopamine, leading to the hypothesis that methylphenidate amplifies basal dopamine activity, leading to nonresponse in those with low basal DA activity.[118] On average, methylphenidate elicits a 3–4 times increase in dopamine and norepinephrine in the striatum and prefrontal cortex.[119] Magnetic resonance imaging (MRI) studies suggest that long-term treatment with ADHD stimulants (specifically, amphetamine and methylphenidate) decreases abnormalities in brain structure and function found in subjects with ADHD.[120] [121] [122]

Both amphetamine and methylphenidate are predominantly dopaminergic drugs, yet their mechanisms of action are distinct. Methylphenidate acts as a norepinephrine–dopamine reuptake inhibitor, while amphetamine is both a releasing agent and reuptake inhibitor of dopamine and norepinephrine. Methylphenidate's mechanism of action in the release of dopamine and norepinephrine is fundamentally different from most other phenethylamine derivatives, as methylphenidate is thought to increase neuronal firing rate,[123] [124] [125] whereas amphetamine reduces firing rate, but causes monoamine release by reversing the flow of the monoamines through monoamine transporters via a diverse set of mechanisms, including TAAR1 activation and modulation of VMAT2 function, among other mechanisms.[126] [127] [128] The difference in mechanism of action between methylphenidate and amphetamine results in methylphenidate inhibiting amphetamine's effects on monoamine transporters when they are co-administered.

Methylphenidate has both dopamine transporter and norepinephrine transporter binding affinity, with the dextromethylphenidate enantiomers displaying a prominent affinity for the norepinephrine transporter.[129] Both the dextrorotary and levorotary enantiomers displayed receptor affinity for the serotonergic 5HT1A and 5HT2B subtypes, though direct binding to the serotonin transporter was not observed. A later study confirmed the d-threo-methylphenidate (dexmethylphenidate) binding to the 5HT1A receptor, but no significant activity on the 5HT2B receptor was found.[130]

There exist some paradoxical findings that oppose the notion that methylphenidate acts as silent antagonist of the DAT (DAT inhibitor). 80% occupancy of the DAT is necessary for methylphenidate's euphoriant effect, but re-administration of methylphenidate beyond this level of DAT occupancy has been found to produce similarly potent euphoriant effects (despite DAT occupancy being unchanged with repeated administration).[131] By contrast, other DAT inhibitors such as bupropion have not been observed to exhibit this effect.[132] These observations have prompted the hypothesis that methylphenidate may act as a "DAT inverse agonist" or "negative allosteric modifier of the DAT" by reversing the direction of the dopamine efflux by the DAT at higher dosages.[133]

Methylphenidate may protect neurons from the neurotoxic effects of Parkinson's disease and methamphetamine use disorder.[134] The hypothesized mechanism of neuroprotection is through inhibition of methamphetamine–DAT interactions, and through reducing cytosolic dopamine, leading to decreased production of dopamine-related reactive oxygen species.

The dextrorotary enantiomers are significantly more potent than the levorotary enantiomers, and some medications therefore only contain dexmethylphenidate. The studied maximized daily dosage of OROS methylphenidate appears to be 144 mg/day.[135]

Pharmacokinetics

Methylphenidate taken by mouth has a bioavailability of 11–52% with a duration of action around 2–4 hours for instant-release (i.e. Ritalin), 3–8 hours for sustained-release (i.e. Ritalin SR), and 8–12 hours for extended-release (i.e. Concerta). The half-life of methylphenidate is 2–3 hours, depending on the individual. The peak plasma time is achieved at about 2 hours.[136] Methylphenidate has a low plasma protein binding of 10–33% and a volume of distribution of 2.65 L/kg.

Dextromethylphenidate is much more bioavailable than levomethylphenidate when administered orally, and is primarily responsible for the psychoactivity of racemic methylphenidate.

The oral bioavailability and speed of absorption for immediate-release methylphenidate is increased when administered with a meal.[137] The effects of a high fat meal on the observed Cmax differ between some extended-release formulations, with combined IR/ER and OROS formulations showing reduced Cmax levels[138] while liquid-based extended-release formulations showed increased Cmax levels when administered with a high-fat meal, according to some researchers.[139] A 2003 study, however, showed no difference between a high-fat meal administration and a fasting administration of oral methylphenidate.[140]

Methylphenidate is metabolized into ritalinic acid by CES1A1 enzymes in the liver. Dextromethylphenidate is selectively metabolized at a slower rate than levomethylphenidate.[141] 97% of the metabolised drug is excreted in the urine, and between 1 and 3% is excreted in the faeces. A small amount, less than 1%, of the drug is excreted in the urine in its unchanged form.

Chemistry

See also: List of methylphenidate analogues. Despite the claim made by some urban legends, it is not a cocaine derivative nor analog; cocaine is a local anesthetic and ligand channel blocker with SNDRI action, while methylphenidate is an NDRI with 2–3 fold selectivity for the dopamine transporter (DAT) over the norepinephrine transporter (NET). Cocaine is also more potent in serotonin transporters (SERTs) than NDRI sites.[142] [143]

Four isomers of methylphenidate are possible, since the molecule has two chiral centers. One pair of threo isomers and one pair of erythro are distinguished, from which primarily d-threo-methylphenidate exhibits the pharmacologically desired effects.[144] The erythro diastereomers are pressor amines, a property not shared with the threo diastereomers. When the drug was first introduced it was sold as a 4:1 mixture of erythro:threo diastereomers, but it was later reformulated to contain only the threo diastereomers. "TMP" refers to a threo product that does not contain any erythro diastereomers, i.e. (±)-threo-methylphenidate. Since the threo isomers are energetically favored, it is easy to epimerize out any of the undesired erythro isomers. The drug that contains only dextrorotatory methylphenidate is sometimes called d-TMP, although this name is only rarely used and it is much more commonly referred to as dexmethylphenidate, d-MPH, or d-threo-methylphenidate. A review on the synthesis of enantiomerically pure (2R,2R)-(+)-threo-methylphenidate hydrochloride has been published.[145]

Detection in biological fluids

The concentration of methylphenidate or ritalinic acid, its major metabolite, may be quantified in plasma, serum or whole blood in order to monitor compliance in those receiving the drug therapeutically, to confirm the diagnosis in potential poisoning victims or to assist in the forensic investigation in a case of fatal overdosage.[146]

History

Methylphenidate was first synthesized in 1944 and was approved for medical use in the United States in 1955.[147] [148] [149] It was synthesized by chemist Leandro Panizzon and sold by Swiss company CIBA (now Novartis). He named the drug after his wife Margarita, nicknamed Rita, who used Ritalin to compensate for low blood pressure.[150] Methylphenidate was not reported to be a stimulant until 1954.[151] [152] The drug was introduced for medical use in the United States in 1957.[153] Originally, it was marketed as a mixture of two racemates, 80% (±)-erythro and 20% (±)-threo, under the brand name Centedrin. Subsequent studies of the racemates showed that the central stimulant activity is associated with the threo racemate and were focused on the separation and interconversion of the erythro isomer into the more active threo isomer.[154] [155] [156] The erythro isomer was eliminated, and now modern formulations of methyphenidate contain only the threo isomer in a 50:50 mixture of d- and l-isomers.

Methylphenidate was first used to allay barbiturate-induced coma, narcolepsy and depression.[157] It was later used to treat memory deficits in the elderly.[158] Beginning in the 1960s, it was used to treat children with ADHD based on earlier work, starting with the studies by American psychiatrist Charles Bradley[159] on the use of psychostimulant drugs, such as Benzedrine, with then called "maladjusted children".[160] Production and prescription of methylphenidate rose significantly in the 1990s, especially in the United States, as the ADHD diagnosis came to be better understood and more generally accepted within the medical and mental health communities.[161]

In 2000, Alza Corporation received US FDA approval to market Concerta, an extended-release form of methylphenidate.[162] [163]

It was estimated that the number of doses of methylphenidate used globally in 2013 increased by 66% compared to 2012.[164] In 2021, it was the 43rd most commonly prescribed medication in the United States, with more than 15million prescriptions.[165] It is available as a generic medication.

Society and culture

Names

Methylphenidate is sold in the majority of countries worldwide.[166] Brand names for methylphenidate include Ritalin (in honor of Rita, the wife of the molecule discoverer), Rilatine (in Belgium to avoid a conflict of commercial name with the RIT pharmaceutical company), Concerta, Medikinet, Adaphen, Addwize, Inspiral, Methmild, Artige, Attenta, Cognil, Konsenidat, Equasym, Foquest,[167] Methylin, Penid, Phenida, Prohiper, and Tradea.

Available forms

The dextrorotary enantiomer of methylphenidate, known as dexmethylphenidate, is sold as a generic and under the brand names Focalin and Attenade in both an immediate-release and an extended-release form. There is some evidence that dexmethylphenidate has better bioavailability and a longer duration of action than methylphenidate.

Immediate-release

Methylphenidate was originally available as an immediate-release racemic mixture formulation under the Novartis brand name Ritalin, although a variety of generics are available, some under other brand names. Generic brand names include Ritalina, Rilatine, Attenta, Medikinet, Metadate, Methylin, Penid, Tranquilyn, and Rubifen.

Extended-release

Extended-release methylphenidate products include:

-- Note that a modified version of this table is in use on https://en.wikipedia.org/wiki/Attention_deficit_hyperactivity_disorder_management#Methylphenidate -->
Brand name(s)Generic name(s)[168] [169] [170] [171] DurationDosage
form
Aptensio XR (US);
Biphentin (CA)		12 hours[172] [173]
capsule
Concerta (US/CA/AU);
Concerta XL (UK)		methylphenidate ER (US/CA);
methylphenidate ER‑C (CA)		12 hours[174]
tablet
Quillivant XR (US)12 hoursoral
suspension
Daytrana (US)methylphenidate film, extended release;transdermal (US)11 hours[175] transdermal
patch
Metadate CD (US);
Equasym XL (UK)		methylphenidate ER (US)8–10 hours
capsule
QuilliChew ER (US)8 hours[176] chewable
tablet
Jornay PM (US)6 hours (following 10 hour delay)[177] DR/ER
capsule
Ritalin LA (US/AU);
Medikinet XL (UK)		methylphenidate ER (US)8 hours
capsule
Ritalin SR (US/CA/UK);
Rubifen SR (NZ)		Metadate ER (US);
Methylin ER (US);
methylphenidate SR (US/CA)		5–8 hours
tablet

Concerta tablets are marked with the letters "ALZA" and followed by: "18", "27", "36", or "54", relating to the dosage strength in milligrams. Approximately 22% of the dose is immediate-release,[178] and the remaining 78% of the dose is released over 10–12 hours post-ingestion, with an initial increase over the first 6–7 hours, and subsequent decline in the released drug.[179]

Ritalin LA capsules are marked with the letters "NVR" (abbrev.: Novartis) and followed by: "R20", "R30", or "R40", depending on the (mg) dosage strength. Ritalin LA provides two standard doses – half the total dose being released immediately and the other half released four hours later. In total, each capsule is effective for about eight hours.

Metadate CD capsules contain two types of beads: 30% are immediate-release, and the other 70% are evenly sustained release.[180]

Medikinet Retard/CR/Adult/Modified Release tablets are an extended-release oral capsule form of methylphenidate. It delivers 50% of the dosage as IR MPH and the remaining 50% in 3–4 hours.[181] [182]

Jornay PM is a delayed release formulation that is taken at bedtime. An outer polymer coating delays the initial release of the drug until 8 hours after administration, after which an inner coating regulates the rate of drug absorption. Peak plasma concentration occurs 14 hours following administration. This formulation was motivated by the need for a pediatric ADHD medication that is active immediately after morning waking, as most long-acting formulations exhibit a delay between administration and absorption that leads to inadequate therapeutic effect in the early morning.[183]

Skin patch

A methylphenidate skin patch is sold under the brand name Daytrana in the United States. It was developed and marketed by Noven Pharmaceuticals and approved in the US in 2006. It is also referred to as methylphenidate transdermal system (MTS). It is approved as a once-daily treatment in children with ADHD aged 6–17 years. It is mainly prescribed as a second-line treatment when oral forms are not well tolerated, or if people have difficulty with compliance. Noven's original FDA submission indicated that it should be used for 12 hours. When the FDA rejected the submission, they requested evidence that a shorter time period was safe and effective; Noven provided such evidence, and it was approved for a 9-hour period.[184]

Orally administered methylphenidate is subject to first-pass metabolism, by which the levo-isomer is extensively metabolized. By circumventing this first-pass metabolism, the relative concentrations of ℓ-threo-methylphenidate are much higher with transdermal administration (50–60% of those of dexmethylphenidate instead of about 14–27%).[185]

A 39 nanograms/mL peak serum concentration of methylphenidate has been found to occur between 7.5–10.5 hours after administration. However, the onset to peak effect is 2 hours, and the clinical effects remain up to 2 hours after the patch has been removed. The absorption is increased when the transdermal patch is applied onto inflamed skin or skin that has been exposed to heat. The absorption lasts for approximately 9 hours after application (onto normal, unexposed to heat and uninflamed skin). 90% of the medication is excreted in the urine as metabolites and unchanged drug.

Parenteral formulation

When it was released in the United States, methylphenidate was available from CIBA in a parenteral form for use by medical professionals. It came in 10mL multiple-dose vials containing 100 mg methylphenidate HCl and 100 mg lactose in lyophilized (freeze-dried) form. It was also available as single-dose ampoules containing 20 mg methylphenidate HCl. Instructions were to reconstitute with 10mL sterile solvent (water). The indication was 10 to 20 mg (1.0mL from MDV's, up to one full single-use ampoule) to produce a focused, talkative state that could help certain patients breakdown the resistance to therapy. Parenteral methylphenidate was discontinued out of a concern for the actual benefit and of inducing a psychic dependence. This is not truth serum in the normal sense, as it does not impair the ability to control the flow of information like a barbiturate agent (Pentothal) or similar might.

Cost

Brand-name and generic formulations are available.

Legal status

Internationally, methylphenidate is a Schedule II drug under the Convention on Psychotropic Substances.[186]

Country/TerritoryStatusNotes
Australia"Schedule 8" controlled substance. Such drugs must be kept in a lockable safe until dispensed and possession without prescription is punishable by fines and imprisonment.[187]
CanadaSchedule III of the Controlled Drugs and Substances Act and is illegal to possess without a prescription, with unlawful possession punishable by up to three years imprisonment, or (via summary conviction) by up to one year imprisonment and/or fines of up to two thousand dollars. Unlawful possession for the purpose of trafficking is punishable by up to ten years imprisonment, or (via summary conviction) by up to eighteen months imprisonment.[188]
FijiSchedule 1 Illicit Drug under the Illicit Drugs Control Act 2004[189]
FranceCovered by the "narcotics" schedule, prescription and distribution conditions are restricted, with hospital or city specialist-only (pediatrician for children, psychiatrist or neurologist for adults) prescription for the initial treatment and yearly consultations.[190]
Hong KongControlled under the schedule 1 of the Dangerous Drugs Ordinance (cap. 134).[191]
IndiaMethylphenidate is a schedule X drug and is controlled by the Drugs and Cosmetics Rules, 1945. It is dispensed only by physician's prescription. Legally, 2 grams of methylphenidate is classified as a small quantity, and 50 grams as a large or commercial quantity.[192] [193]
New ZealandIn New Zealand, methylphenidate is a "class B2 controlled substance". Unlawful possession is punishable by six-month prison sentence and distribution by a 14-year sentence.
List I controlled psychotropic substance without recognized medical value. The Constant Committee for Drug Control of the Russian Ministry of Health has put methylphenidate and its derivatives on the National List of Narcotics, Psychotropic Substances and Their Precursors, and the Government banned methylphenidate for any use on 25 October 2014.[194]
SwedenList II controlled substance with recognized medical value. Possession without a prescription is punishable by up to three years in prison.[195]
United KingdomControlled "Class B" substance. Possession without prescription carries a sentence up to 5 years or an unlimited fine, or both; supplying methylphenidate is 14 years or an unlimited fine, or both.[196]
United StatesClassified as a Schedule II controlled substance, the designation used for substances that have a recognized medical value but present a high potential for misuse.[197]

Controversy

Methylphenidate has been the subject of controversy in relation to its use in the treatment of ADHD. The prescription of psychostimulant medication to children to reduce ADHD symptoms has been a major point of criticism.[198] The contention that methylphenidate acts as a gateway drug has been discredited by multiple sources,[199] according to which abuse is statistically very low and "stimulant therapy in childhood does not increase the risk for subsequent drug and alcohol abuse disorders later in life".[200] A study found that ADHD medication was not associated with an increased risk of cigarette use, and in fact, stimulant treatments such as Ritalin seemed to lower this risk.[201] People treated with stimulants such as methylphenidate during childhood were less likely to have substance use disorders in adulthood.[202]

Among countries with the highest rates of use of methylphenidate medication is Iceland,[203] where research shows that the drug was the most commonly used substance among people who inject drugs.[204] The study involved 108 people who inject drugs and 88% of them had injected methylphenidate within the last 30 days and for 63% of them, methylphenidate was the most preferred substance.

Treatment of ADHD by way of methylphenidate has led to legal actions, including malpractice suits regarding informed consent, inadequate information on side effects, misdiagnosis, and coercive use of medications by school systems.[205]

Research

Apathy

Methylphenidate may be effective as a treatment for apathy in Alzheimer's disease and other conditions.[206] [207] [208] [209] It may also be useful in the treatment of more severe disorders of diminished motivation, like abulia and akinetic mutism.[210]

Addiction

Methylphenidate has shown some benefits as a replacement therapy for individuals who are addicted to and dependent upon methamphetamine.[211] Methylphenidate and amphetamine have been investigated as a chemical replacement for the treatment of cocaine addiction.[212] [213] Its effectiveness in treatment of cocaine or psychostimulant addiction or psychological dependence has not been proven.[214]

Social anxiety

Methylphenidate has been reported to be effective in the treatment of social anxiety disorder in people who are comorbid for both this condition and attention deficit hyperactivity disorder (ADHD) in small preliminary clinical studies and case reports.[215] [216] [217] [218] [219] [220]

External links

]

Notes and References

  1. Book: Bonewit-West K, Hunt SA, Applegate E . 2012 . Today's Medical Assistant: Clinical and administrative procedures . Elsevier Health Sciences . 978-1-4557-0150-6 . 571 . live . 20 August 2019 . 28 July 2020 . https://web.archive.org/web/20200728034412/https://books.google.com/books?id=YalYPI1KqTQC&pg=PA571.
  2. Web site: Anvisa . Brazilian Health Regulatory Agency . 31 March 2023 . RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial . Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control. live . https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 . 3 August 2023 . 3 August 2023 . . pt-BR . 4 April 2023.
  3. Web site: Ritalin Product information . Health Canada . 25 April 2012 . 11 June 2022 . 11 June 2022 . https://web.archive.org/web/20220611233512/https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=800 . live .
  4. Web site: Controlled Drugs and Substances Act . Justice Laws Website . 31 March 2022 . 11 June 2022 . 21 August 2021 . https://web.archive.org/web/20210821102842/https://laws-lois.justice.gc.ca/eng/acts/c-38.8/fulltext.html . live .
  5. Web site: Mental health . . 9 May 2018 . 13 April 2024.
  6. Web site: Ritalin- methylphenidate hydrochloride tablet . DailyMed . 26 June 2021 . 26 March 2022 . 20 March 2017 . https://web.archive.org/web/20170320052349/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0bf0835-6a2f-4067-a158-8b86c4b0668a . live .
  7. Web site: Ritalin LA- methylphenidate hydrochloride capsule, extended release . DailyMed . 26 June 2021 . 26 March 2022 . 26 March 2017 . https://web.archive.org/web/20170326230529/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=effd952d-ac94-47bb-b107-589a4934dcca . live .
  8. Web site: Concerta- methylphenidate hydrochloride tablet, extended release . DailyMed . 1 July 2021 . 26 March 2022 . 26 March 2017 . https://web.archive.org/web/20170326230808/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a88218c-5b18-4220-8f56-526de1a276cd . live .
  9. Web site: Daytrana- methylphenidate patch . DailyMed . 15 June 2021 . 26 March 2022 . 19 March 2022 . https://web.archive.org/web/20220319232456/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c312c31-3198-4775-91ab-294e0b4b9e7f . live .
  10. Web site: Methylphenidate. Pubchem. 4 September 2017. 6 January 2014. https://web.archive.org/web/20140106100442/http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=4158#x27. live.
  11. Web site: 24 December 2021 . Attention deficit hyperactivity disorder (ADHD): Treatment . 18 October 2022 . National Health Service (NHS).
  12. Web site: Methylphenidate Hydrochloride Monograph for Professionals . Drugs.com . AHFS . 19 December 2018 . https://web.archive.org/web/20181219182550/https://www.drugs.com/monograph/methylphenidate-hydrochloride.html . 19 December 2018 . live .
  13. Bushe C, Day K, Reed V, Karlsdotter K, Berggren L, Pitcher A, Televantou F, Haynes V . A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients . Journal of Psychopharmacology . 30 . 5 . 444–458 . May 2016 . 27005307 . 10.1177/0269881116636105 . 104938 .
  14. Hazell PL, Kohn MR, Dickson R, Walton RJ, Granger RE, Wyk GW . Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis . Journal of Attention Disorders . 15 . 8 . 674–683 . November 2011 . 20837981 . 10.1177/1087054710379737 . 43503227 .
  15. Hanwella R, Senanayake M, de Silva V . Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis . BMC Psychiatry . 11 . 1 . 176 . November 2011 . 22074258 . 3229459 . 10.1186/1471-244X-11-176 . free .
  16. Rezaei G, Hosseini SA, Akbari Sari A, Olyaeemanesh A, Lotfi MH, Yassini M, Bidaki R, Nouri B . Comparative efficacy of methylphenidate and atomoxetine in the treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review and meta-analysis . Medical Journal of the Islamic Republic of Iran . 30 . 325 . 10 February 2016 . 27390695 . 4898838 .
  17. Stuhec M, Lukić P, Locatelli I . Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis . The Annals of Pharmacotherapy . 53 . 2 . 121–133 . February 2019 . 30117329 . 10.1177/1060028018795703 . 52019992 .
  18. Faraone SV, Pliszka SR, Olvera RL, Skolnik R, Biederman J . Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a reanalysis using drug-placebo and drug-drug response curve methodology . Journal of Child and Adolescent Psychopharmacology . 11 . 2 . 171–180 . June 2001 . 11436957 . 10.1089/104454601750284081 . .
  19. Faraone SV, Biederman J, Roe C . Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis . Journal of Clinical Psychopharmacology . 22 . 5 . 468–473 . October 2002 . 12352269 . 10.1097/00004714-200210000-00005 . 19726926 .
  20. Faraone SV, Buitelaar J . Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis . European Child & Adolescent Psychiatry . 19 . 4 . 353–364 . April 2010 . 19763664 . 10.1007/s00787-009-0054-3 . 9447892 .
  21. Isfandnia F, El Masri S, Radua J, Rubia K . The effects of chronic administration of stimulant and non-stimulant medications on executive functions in ADHD: A systematic review and meta-analysis . Neuroscience and Biobehavioral Reviews . 162 . 105703 . July 2024 . 38718988 . 10.1016/j.neubiorev.2024.105703 .
  22. Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, Newcorn JH, Gignac M, Al Saud NM, Manor I, Rohde LA, Yang L, Cortese S, Almagor D, Stein MA, Albatti TH, Aljoudi HF, Alqahtani MM, Asherson P, Atwoli L, Bölte S, Buitelaar JK, Crunelle CL, Daley D, Dalsgaard S, Döpfner M, Espinet S, Fitzgerald M, Franke B, Gerlach M, Haavik J, Hartman CA, Hartung CM, Hinshaw SP, Hoekstra PJ, Hollis C, Kollins SH, Sandra Kooij JJ, Kuntsi J, Larsson H, Li T, Liu J, Merzon E, Mattingly G, Mattos P, McCarthy S, Mikami AY, Molina BS, Nigg JT, Purper-Ouakil D, Omigbodun OO, Polanczyk GV, Pollak Y, Poulton AS, Rajkumar RP, Reding A, Reif A, Rubia K, Rucklidge J, Romanos M, Ramos-Quiroga JA, Schellekens A, Scheres A, Schoeman R, Schweitzer JB, Shah H, Solanto MV, Sonuga-Barke E, Soutullo C, Steinhausen HC, Swanson JM, Thapar A, Tripp G, van de Glind G, van den Brink W, Van der Oord S, Venter A, Vitiello B, Walitza S, Wang Y . The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder . Neuroscience and Biobehavioral Reviews . 128 . 789–818 . September 2021 . 33549739 . 8328933 . 10.1016/j.neubiorev.2021.01.022 .
  23. https://psycnet.apa.org/record/2014-21941-001
  24. Arnsten AF, Li BM . Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions . Biological Psychiatry . 57 . 11 . 1377–1384 . June 2005 . 15950011 . 10.1016/j.biopsych.2004.08.019 . 22992765 .
  25. Book: Stahl SM . 11 April 2013 . Stahl's Essential Psychopharmacology: Neuroscientific basis and practical applications . Cambridge University Press . 978-1-107-68646-5 . 4th.
  26. Web site: Methylphenidate Monograph for Professionals . Drugs.com . American Society of Health-System Pharmacists . 2 February 2019 . en . 3 February 2019 . https://web.archive.org/web/20190203030724/https://www.drugs.com/monograph/methylphenidate.html . live .
  27. Web site: The Top 300 of 2021 . ClinCalc . 14 January 2024 . 15 January 2024 . https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  28. Web site: Methylphenidate - Drug Usage Statistics . ClinCalc . 14 January 2024.
  29. Web site: Tappy B . Every molecule tells a story: Ritalin - Chronique - Corpore Sano - InVivo . www.invivomagazine.com . 12 March 2024.
  30. Web site: Methylphenidate . DrugBank . 30 January 2019 . https://web.archive.org/web/20190131040915/https://www.drugbank.ca/drugs/DB00422 . 31 January 2019 .
  31. Fone KC, Nutt DJ . Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder . Current Opinion in Pharmacology . 5 . 1 . 87–93 . February 2005 . 15661631 . 10.1016/j.coph.2004.10.001 .
  32. Huss M, Duhan P, Gandhi P, Chen CW, Spannhuth C, Kumar V . Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity . Neuropsychiatric Disease and Treatment . 13 . 1741–1751 . 2 June 2021 . 28740389 . 5505611 . 10.2147/NDT.S130444 . free .
  33. Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, Ganiats TG, Kaplanek B, Meyer B, Perrin J, Pierce K, Reiff M, Stein MT, Visser S . ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit / hyperactivity disorder in children and adolescents . Pediatrics . 128 . 5 . 1007–1022 . November 2011 . 22003063 . 4500647 . 10.1542/peds.2011-2654 .
  34. Book: Neinstein L . 2009 . Handbook of Adolescent Health Care . Wolters Kluwer Health / Lippincott Williams & Wilkins . Philadelphia, PA . 978-0-7817-9020-8 . 226304727 .
  35. Vitiello B . October 2001 . Psychopharmacology for young children: clinical needs and research opportunities . Pediatrics . 108 . 4 . 983–989 . 11581454 . 10.1542/peds.108.4.983 . 33417584 .
  36. Hermens DF, Rowe DL, Gordon E, Williams LM . May 2006 . Integrative neuroscience approach to predict ADHD stimulant response . Expert Review of Neurotherapeutics . 6 . 5 . 753–763 . 16734523 . 10.1586/14737175.6.5.753 . 15971025 .
  37. Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, Newcorn JH, Gignac M, Al Saud NM, Manor I, Rohde LA, Yang L, Cortese S, Almagor D, Stein MA, Albatti TH, Aljoudi HF, Alqahtani MM, Asherson P, Atwoli L, Bölte S, Buitelaar JK, Crunelle CL, Daley D, Dalsgaard S, Döpfner M, Espinet S, Fitzgerald M, Franke B, Gerlach M, Haavik J, Hartman CA, Hartung CM, Hinshaw SP, Hoekstra PJ, Hollis C, Kollins SH, Sandra Kooij JJ, Kuntsi J, Larsson H, Li T, Liu J, Merzon E, Mattingly G, Mattos P, McCarthy S, Mikami AY, Molina BS, Nigg JT, Purper-Ouakil D, Omigbodun OO, Polanczyk GV, Pollak Y, Poulton AS, Rajkumar RP, Reding A, Reif A, Rubia K, Rucklidge J, Romanos M, Ramos-Quiroga JA, Schellekens A, Scheres A, Schoeman R, Schweitzer JB, Shah H, Solanto MV, Sonuga-Barke E, Soutullo C, Steinhausen HC, Swanson JM, Thapar A, Tripp G, van de Glind G, van den Brink W, Van der Oord S, Venter A, Vitiello B, Walitza S, Wang Y . September 2021 . The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder . Neuroscience and Biobehavioral Reviews . 128 . 789–818 . 10.1016/j.neubiorev.2021.01.022 . 8328933 . 33549739.
  38. Web site: eEML - Electronic Essential Medicines List . list.essentialmeds.org . 26 March 2020 . 26 March 2020 . https://web.archive.org/web/20200326025659/https://list.essentialmeds.org/recommendations/1200 . live .
  39. Web site: A.21 Methylphenidate – attention-deficit hyperactivity disorder – EML and EMLc . 2024-05-01 . www.who.int . en.
  40. Web site: Mental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders . 2024-05-01 . www.who.int . en.
  41. https://applications.emro.who.int/docs/EMRPUB_leaflet_2019_mnh_214_en.pdf
  42. Cortese S, Coghill D, Fegert JM, Mattingly GW, Rohde LA, Wong IC, Faraone SV . ESCAP endorses the inclusion of methylphenidate in the WHO model lists of essential medicines and in the Union list of critical medicines . European Child & Adolescent Psychiatry . 33 . 5 . 1605–1608 . May 2024 . 38662057 . 10.1007/s00787-024-02443-5 .
  43. Cortese S, Coghill D, Mattingly GW, Rohde LA, Thom RP, Wilens TE, Wong IC, Faraone SV . AACAP Endorses the Inclusion of Methylphenidate in the WHO Model Lists of Essential Medicines . Journal of the American Academy of Child and Adolescent Psychiatry . 63 . 7 . 663–665 . July 2024 . 38428579 . 10.1016/j.jaac.2024.02.008 .
  44. Abelman DD . Mitigating risks of students use of study drugs through understanding motivations for use and applying harm reduction theory: a literature review . Harm Reduction Journal . 14 . 1 . 68 . October 2017 . 28985738 . 5639593 . 10.1186/s12954-017-0194-6 . free .
  45. Zhang L, Yao H, Li L, Du Rietz E, Andell P, Garcia-Argibay M, D'Onofrio BM, Cortese S, Larsson H, Chang Z . Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis . JAMA Network Open . 5 . 11 . e2243597 . November 2022 . 36416824 . 9685490 . 10.1001/jamanetworkopen.2022.43597 .
  46. Liang EF, Lim SZ, Tam WW, Ho CS, Zhang MW, McIntyre RS, Ho RC . The Effect of Methylphenidate and Atomoxetine on Heart Rate and Systolic Blood Pressure in Young People and Adults with Attention-Deficit Hyperactivity Disorder (ADHD): Systematic Review, Meta-Analysis, and Meta-Regression . International Journal of Environmental Research and Public Health . 15 . 8 . 1789 . August 2018 . 30127314 . 6121294 . 10.3390/ijerph15081789 . free .
  47. Liu H, Feng W, Zhang D . Association of ADHD medications with the risk of cardiovascular diseases: a meta-analysis . European Child & Adolescent Psychiatry . 28 . 10 . 1283–1293 . October 2019 . 30143889 . 10.1007/s00787-018-1217-x .
  48. Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV . ADHD medications and risk of serious cardiovascular events in young and middle-aged adults . JAMA . 306 . 24 . 2673–2683 . December 2011 . 22161946 . 3350308 . 10.1001/jama.2011.1830 .
  49. Fry JM . Treatment modalities for narcolepsy . Neurology . 50 . 2 Suppl 1 . S43–S48 . February 1998 . 9484423 . 10.1212/WNL.50.2_Suppl_1.S43 . 36824088 .
  50. Mitler MM . Evaluation of treatment with stimulants in narcolepsy . Sleep . 17 . 8 Suppl . S103–S106 . December 1994 . 7701190 . 10.1093/sleep/17.suppl_8.S103 . free .
  51. Dell'Osso B, Dobrea C, Cremaschi L, Arici C, Altamura AC . Wake-promoting pharmacotherapy for psychiatric disorders . Current Psychiatry Reports . 16 . 12 . 524 . December 2014 . 25312027 . 10.1007/s11920-014-0524-2 . 26314915 .
  52. Leonard BE, McCartan D, White J, King DJ . Methylphenidate: A review of its neuropharmacological, neuropsychological, and adverse clinical effects . Human Psychopharmacology . 19 . 3 . 151–180 . April 2004 . 15079851 . 10.1002/hup.579 . 21173346 .
  53. Bahji A, Mesbah-Oskui L . Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis . Journal of Affective Disorders . 292 . 416–423 . September 2021 . 34144366 . 10.1016/j.jad.2021.05.119 .
  54. Pary R, Scarff JR, Jijakli A, Tobias C, Lippmann S . A Review of Psychostimulants for Adults With Depression . Federal Practitioner . 32 . Suppl 3 . 30S–37S . April 2015 . 30766117 . 6375494 .
  55. Rozans M, Dreisbach A, Lertora JJ, Kahn MJ . Palliative uses of methylphenidate in patients with cancer: a review . Journal of Clinical Oncology . 20 . 1 . 335–339 . January 2002 . 11773187 . 10.1200/JCO.20.1.335 .
  56. Smith KR, Kahlon CH, Brown JN, Britt RB . Methylphenidate use in geriatric depression: A systematic review . International Journal of Geriatric Psychiatry . 36 . 9 . 1304–1312 . September 2021 . 33829530 . 10.1002/gps.5536 . 233184870 .
  57. Ruthirakuhan MT, Herrmann N, Abraham EH, Chan S, Lanctôt KL . Pharmacological interventions for apathy in Alzheimer's disease . The Cochrane Database of Systematic Reviews . 5 . 6 . CD012197 . May 2018 . 29727467 . 6494556 . 10.1002/14651858.CD012197.pub2 .
  58. Web site: 1 June 2018 . Attention deficit hyperactivity disorder (ADHD) . Treatment . 24 October 2022 . nhs.uk . en.
  59. Robison LS, Ananth M, Hadjiargyrou M, Komatsu DE, Thanos PK . Chronic oral methylphenidate treatment reversibly increases striatal dopamine transporter and dopamine type 1 receptor binding in rats . Journal of Neural Transmission . 124 . 5 . 655–667 . May 2017 . 28116523 . 5400672 . 10.1007/s00702-017-1680-4 .
  60. Spencer RC, Devilbiss DM, Berridge CW . The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex . Biological Psychiatry . 77 . 11 . 940–950 . June 2015 . 25499957 . 4377121 . 10.1016/j.biopsych.2014.09.013 .
  61. Ilieva IP, Hook CJ, Farah MJ . Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis . Journal of Cognitive Neuroscience . 27 . 6 . 1069–1089 . June 2015 . 25591060 . 10.1162/jocn_a_00776 . 15788121 . 12 June 2022 . 26 May 2022 . https://web.archive.org/web/20220526103820/https://repository.upenn.edu/cgi/viewcontent.cgi?article=1141&context=neuroethics_pubs . live .
  62. Busardò FP, Kyriakou C, Cipolloni L, Zaami S, Frati P . From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate . Current Neuropharmacology . 14 . 1 . 17–27 . 2016 . 26813119 . 4787280 . 10.2174/1570159x13666150407225902 .
  63. Carlier J, Giorgetti R, Varì MR, Pirani F, Ricci G, Busardò FP . Use of cognitive enhancers: methylphenidate and analogs . European Review for Medical and Pharmacological Sciences . 23 . 1 . 3–15 . January 2019 . 30657540 . 10.26355/eurrev_201901_16741 . 58643522 .
  64. Repantis D, Bovy L, Ohla K, Kühn S, Dresler M . Cognitive enhancement effects of stimulants: a randomized controlled trial testing methylphenidate, modafinil, and caffeine . Psychopharmacology . 238 . 2 . 441–451 . February 2021 . 33201262 . 7826302 . 10.1007/s00213-020-05691-w .
  65. Montgomery KA . Sexual desire disorders . Psychiatry . 5 . 6 . 50–55 . June 2008 . 19727285 . 2695750 .
  66. Berezanskaya J, Cade W, Best TM, Paultre K, Kienstra C . ADHD Prescription Medications and Their Effect on Athletic Performance: A Systematic Review and Meta-analysis . Sports Medicine - Open . 8 . 1 . 5 . January 2022 . 35022919 . 8755863 . 10.1186/s40798-021-00374-y . free .
  67. Thoenes MM . Heat-related illness risk with methylphenidate use . English . Journal of Pediatric Health Care . 25 . 2 . 127–132 . 1 March 2011 . 21320685 . 10.1016/j.pedhc.2010.07.006 .
  68. Docherty JR, Alsufyani HA . Cardiovascular and temperature adverse actions of stimulants . British Journal of Pharmacology . 178 . 13 . 2551–2568 . July 2021 . 33786822 . 10.1111/bph.15465 . 232431910 . free .
  69. Spencer RC, Devilbiss DM, Berridge CW . The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex . Biological Psychiatry . 77 . 11 . 940–950 . June 2015 . 25499957 . 4377121 . 10.1016/j.biopsych.2014.09.013.
  70. Ilieva IP, Hook CJ, Farah MJ . Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis . Journal of Cognitive Neuroscience . 27 . 6 . 1069–1089 . June 2015 . 25591060 . 10.1162/jocn_a_00776 . 14 November 2018 . live . 15788121 . https://web.archive.org/web/20180919111616/https://repository.upenn.edu/neuroethics_pubs/130/ . 19 September 2018 .
  71. Wood S, Sage JR, Shuman T, Anagnostaras SG . Psychostimulants and cognition: a continuum of behavioral and cognitive activation . Pharmacological Reviews . 66 . 1 . 193–221 . January 2014 . 24344115 . 3880463 . 10.1124/pr.112.007054 .
  72. Book: Malenka RC, Nestler EJ, Hyman SE . Sydor A, Brown RY . 2009 . Higher cognitive function and behavioral control . Molecular Neuropharmacology: A foundation for clinical neuroscience . McGraw-Hill Medical . New York, NY . 978-0-07-148127-4 . 318 . 2nd.
  73. Agay N, Yechiam E, Carmel Z, Levkovitz Y . Non-specific effects of methylphenidate (Ritalin) on cognitive ability and decision-making of ADHD and healthy adults . Psychopharmacology . 210 . 4 . 511–519 . July 2010 . 20424828 . 10.1007/s00213-010-1853-4 . 17083986.
  74. Web site: JS Online . Twohey M . 26 March 2006 . Pills become an addictive study aid . 2 December 2007 . https://web.archive.org/web/20070815200239/http://www.jsonline.com/story/index.aspx?id=410902 . 15 August 2007.
  75. Teter CJ, McCabe SE, LaGrange K, Cranford JA, Boyd CJ . Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration . Pharmacotherapy . 26 . 10 . 1501–1510 . October 2006 . 16999660 . 1794223 . 10.1592/phco.26.10.1501.
  76. Roelands B, de Koning J, Foster C, Hettinga F, Meeusen R . Neurophysiological determinants of theoretical concepts and mechanisms involved in pacing . Sports Medicine . 43 . 5 . 301–311 . May 2013 . 23456493 . 10.1007/s40279-013-0030-4 . 30392999 .
  77. Web site: Methylphenidate: Use During Pregnancy and Breastfeeding . https://web.archive.org/web/20180102005138/https://www.drugs.com/pregnancy/methylphenidate.html . 2 January 2018 . Drugs.com .
  78. Humphreys C, Garcia-Bournissen F, Ito S, Koren G . Exposure to attention deficit hyperactivity disorder medications during pregnancy . Canadian Family Physician . 53 . 7 . 1153–1155 . July 2007 . 17872810 . 1949295 .
  79. Ornoy A . Pharmacological Treatment of Attention Deficit Hyperactivity Disorder During Pregnancy and Lactation . Pharmaceutical Research . 35 . 3 . 46 . February 2018 . 29411149 . 10.1007/s11095-017-2323-z . 3663423 .
  80. Coghill D, Banaschewski T, Zuddas A, Pelaz A, Gagliano A, Doepfner M . September 2013 . Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies . BMC Psychiatry . Springer Science and Business Media LLC . 13 . 1 . 237 . 10.1186/1471-244x-13-237 . 3852277 . 24074240 . free .
  81. Web site: Ritalin LA (methylphenidate hydrochloride) extended-release capsules . https://web.archive.org/web/20110720004745/http://www.pharma.us.novartis.com/product/pi/pdf/ritalin_la.pdf . 20 July 2011 . Novartis.
  82. Jaanus SD . Ocular side effects of selected systemic drugs . Optometry Clinics . 2 . 4 . 73–96 . 1992 . 1363080 .
  83. Peterson BS, Trampush J, Maglione M, Bolshakova M, Rozelle M, Miles J, Pakdaman S, Brown M, Yagyu S, Motala A, Hempel S . Treatments for ADHD in Children and Adolescents: A Systematic Review . Pediatrics . 153 . 4 . April 2024 . 38523592 . 10.1542/peds.2024-065787 .
  84. Bron TI, Bijlenga D, Kasander MV, Spuijbroek AT, Beekman AT, Kooij JJ . June 2013 . Long-term relationship between methylphenidate and tobacco consumption and nicotine craving in adults with ADHD in a prospective cohort study . European Neuropsychopharmacology . 23 . 6 . 542–554 . 10.1016/j.euroneuro.2012.06.004 . 22809706 . 23148548.
  85. Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Graham J, Taylor E, Sergeant J . Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents . Journal of Child Psychology and Psychiatry, and Allied Disciplines . 54 . 3 . 227–246 . March 2013 . 23294014 . 10.1111/jcpp.12036 .
  86. Poulton A . Growth on stimulant medication; clarifying the confusion: a review . Archives of Disease in Childhood . 90 . 8 . 801–806 . August 2005 . 16040876 . 1720538 . 10.1136/adc.2004.056952.
  87. Hinshaw SP, Arnold LE . ADHD, Multimodal Treatment, and Longitudinal outcome: Evidence, paradox, and challenge . Wiley Interdisciplinary Reviews. Cognitive Science . 6 . 1 . 39–52 . January 2015 . 25558298 . 4280855 . 10.1002/wcs.1324 .
  88. Findling RL, Dinh S . Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS) . CNS Drugs . 28 . 3 . 217–228 . March 2014 . 24532028 . 3933749 . 10.1007/s40263-014-0141-y .
  89. Kraemer M, Uekermann J, Wiltfang J, Kis B . Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature . Clinical Neuropharmacology . 33 . 4 . 204–206 . July 2010 . 20571380 . 10.1097/WNF.0b013e3181e29174 . 34956456 .
  90. Wingo AP, Ghaemi SN . Frequency of stimulant treatment and of stimulant-associated mania / hypomania in bipolar disorder patients . Psychopharmacology Bulletin . 41 . 4 . 37–47 . 2008 . 19015628 .
  91. de Sousa A, Kalra G . Drug therapy of attention deficit hyperactivity disorder: current trends . Mens Sana Monographs . 10 . 1 . 45–69 . January 2012 . 22654382 . 3353606 . 10.4103/0973-1229.87261 . 30 March 2024 . free .
  92. Web site: Methylphenidate ADHD medications: Drug safety communication – risk of long-lasting erections . U.S. Food and Drug Administration (FDA) . 17 December 2013 . 17 December 2013 . https://web.archive.org/web/20131217225515/https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm378876.htm. 17 December 2013. dead.
  93. Web site: FDA drug safety communication: Safety review update of medications used to treat attention-ceficit / hyperactivity disorder (ADHD) in children and young adults . 20 December 2011 . U.S. Food and Drug Administration (FDA) . 4 November 2013 . https://web.archive.org/web/20131030042927/https://www.fda.gov/Drugs/DrugSafety/ucm277770.htm . 30 October 2013 . live .

    Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell FA, Ray WA . ADHD drugs and serious cardiovascular events in children and young adults . The New England Journal of Medicine . 365 . 20 . 1896–1904 . November 2011 . 22043968 . 4943074 . 10.1056/NEJMoa1110212 .

    Web site: FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults . 15 December 2011 . U.S. Food and Drug Administration (FDA) . 4 November 2013 . https://web.archive.org/web/20131030064843/https://www.fda.gov/Drugs/DrugSafety/ucm279858.htm . 30 October 2013 . live .

    Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV . ADHD medications and risk of serious cardiovascular events in young and middle-aged adults . JAMA . 306 . 24 . 2673–2683 . December 2011 . 22161946 . 3350308 . 10.1001/jama.2011.1830 .

  94. Gordon N . Attention deficit hyperactivity disorder: Possible causes and treatment . International Journal of Clinical Practice . 53 . 7 . 524–528 . 1999 . 10.1111/j.1742-1241.1999.tb11794.x . 10692738 . 27462347 .
  95. Storebø OJ, Pedersen N, Ramstad E, Kielsholm ML, Nielsen SS, Krogh HB, Moreira-Maia CR, Magnusson FL, Holmskov M, Gerner T, Skoog M, Rosendal S, Groth C, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Håkonsen SJ, Aagaard L, Simonsen E, Gluud C . Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies . The Cochrane Database of Systematic Reviews . 5 . CD012069 . May 2018 . 5 . 29744873 . 6494554 . 10.1002/14651858.CD012069.pub2 . Systematic Review .
  96. Web site: Heedes G, Ailakis J . Methylphenidate hydrochloride (PIM 344) . INCHEM . International Programme on Chemical Safety. 23 June 2015 . https://web.archive.org/web/20150623102325/http://www.inchem.org/documents/pims/pharm/pim344.htm . 23 June 2015 . live.
  97. Spiller HA, Hays HL, Aleguas A . Overdose of drugs for attention-deficit hyperactivity disorder: Clinical presentation, mechanisms of toxicity, and management . CNS Drugs . 27 . 7 . 531–543 . July 2013 . 23757186 . 10.1007/s40263-013-0084-8 . 40931380 . free .
  98. Bruggisser M, Bodmer M, Liechti ME . Severe toxicity due to injected but not oral or nasal abuse of methylphenidate tablets . Swiss Medical Weekly . 141 . w13267 . 2011 . 21984207 . 10.4414/smw.2011.13267 . free .
  99. Morton WA, Stockton GG . Methylphenidate Abuse and Psychiatric Side Effects . Primary Care Companion to the Journal of Clinical Psychiatry . 2 . 5 . 159–164 . October 2000 . 15014637 . 181133 . 10.4088/PCC.v02n0502 .
  100. Auger RR, Goodman SH, Silber MH, Krahn LE, Pankratz VS, Slocumb NL . Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: A case-control study . Sleep . 28 . 6 . 667–672 . June 2005 . 16477952 . 10.1093/sleep/28.6.667 . free .
  101. Book: Malenka RC, Nestler EJ, Hyman SE . Sydor A, Brown RY . 2009 . Chapter 15: Reinforcement and addictive disorders . Molecular Neuropharmacology: A foundation for clinical neuroscience . McGraw-Hill Medical . New York . 978-0-07-148127-4 . 368 . 2nd.
  102. Ishii M, Tatsuzawa Y, Yoshino A, Nomura S . Serotonin syndrome induced by augmentation of SSRI with methylphenidate . Psychiatry and Clinical Neurosciences . 62 . 2 . 246 . April 2008 . 18412855 . 10.1111/j.1440-1819.2008.01767.x . 5659107 . free .
  103. Türkoğlu S . Serotonin syndrome with sertraline and methylphenidate in an adolescent . Clinical Neuropharmacology . 38 . 2 . 65–66 . 2015 . 25768857 . 10.1097/WNF.0000000000000075 . 38523209 .
  104. Park YM, Jung YK . Manic switch and serotonin syndrome induced by augmentation of paroxetine with methylphenidate in a patient with major depression . Progress in Neuro-Psychopharmacology & Biological Psychiatry . 34 . 4 . 719–720 . May 2010 . 20298736 . 10.1016/j.pnpbp.2010.03.016 . 31984813 .
  105. Bodner RA, Lynch T, Lewis L, Kahn D . Serotonin syndrome . Neurology . 45 . 2 . 219–223 . February 1995 . 7854515 . 10.1212/wnl.45.2.219 . 35190429 .
  106. Patrick KS, González MA, Straughn AB, Markowitz JS . New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder . Expert Opinion on Drug Delivery . 2 . 1 . 121–143 . January 2005 . 16296740 . 10.1517/17425247.2.1.121 . 25026467 .
  107. Markowitz JS, DeVane CL, Boulton DW, Nahas Z, Risch SC, Diamond F, Patrick KS . Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol . Drug Metabolism and Disposition . 28 . 6 . 620–624 . June 2000 . 10820132 .
  108. Markowitz JS, Logan BK, Diamond F, Patrick KS . Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion . Journal of Clinical Psychopharmacology . 19 . 4 . 362–366 . August 1999 . 10440465 . 10.1097/00004714-199908000-00013 .
  109. Patrick KS, Straughn AB, Minhinnett RR, Yeatts SD, Herrin AE, DeVane CL, Malcolm R, Janis GC, Markowitz JS . Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics . Clinical Pharmacology and Therapeutics . 81 . 3 . 346–353 . March 2007 . 17339864 . 3188424 . 10.1038/sj.clpt.6100082 .
  110. Roberts SM, DeMott RP, James RC . Adrenergic modulation of hepatotoxicity . Drug Metabolism Reviews . 29 . 1–2 . 329–353 . 1997 . 9187524 . 10.3109/03602539709037587 .
  111. Markowitz JS, Patrick KS . Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: Does chirality matter? . Journal of Clinical Psychopharmacology . 28 . 3 Suppl 2 . S54–S61 . June 2008 . 18480678 . 10.1097/JCP.0b013e3181733560 .
  112. Williard RL, Middaugh LD, Zhu HJ, Patrick KS . Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity . Behavioural Pharmacology . 18 . 1 . 39–51 . February 2007 . 17218796 . 10.1097/fbp.0b013e3280143226 . 20232871 .
  113. Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R . A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study . Journal of Child and Adolescent Psychopharmacology . 16 . 6 . 687–698 . December 2006 . 17201613 . 10.1089/cap.2006.16.687 . 22895177 .
  114. Book: Malenka RC, Nestler EJ, Hyman SE . 2009 . Chapter 6: Widely projecting systems: Monoamines, acetylcholine, and orexin . Sydor A, Brown RY . Molecular Neuropharmacology: A foundation for clinical neuroscience . McGraw-Hill Medical . New York . 978-0-07-148127-4 . 154–157 . 2nd.
  115. Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE . A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder . The Canadian Journal of Clinical Pharmacology . 13 . 1 . e50–e62 . 2006 . 16456216 . dead . http://webarchive.nationalarchives.gov.uk/20111215210932/http%3A//www.cjcp.ca/CJCP_05%2D012_e50%2Dr101628 . 15 December 2011 .
  116. Heal DJ, Pierce DM . Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system . CNS Drugs . 20 . 9 . 713–738 . 2006 . 16953648 . 10.2165/00023210-200620090-00002 . 39535277 .
  117. Iversen L . Neurotransmitter transporters and their impact on the development of psychopharmacology . British Journal of Pharmacology . 147 . Suppl 1 . S82–S88 . January 2006 . 16402124 . 1760736 . 10.1038/sj.bjp.0706428 .
  118. Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ . Mechanism of action of methylphenidate: insights from PET imaging studies . Journal of Attention Disorders . 6 . Suppl 1 . S31–S43 . 1 January 2002 . 12685517 . 10.1177/070674370200601s05 . 9132302 .
  119. Hodgkins P, Shaw M, Coghill D, Hechtman L . Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options . European Child & Adolescent Psychiatry . 21 . 9 . 477–492 . September 2012 . 22763750 . 3432777 . 10.1007/s00787-012-0286-5 .
  120. Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K . Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects . JAMA Psychiatry . 70 . 2 . 185–198 . February 2013 . 23247506 . 10.1001/jamapsychiatry.2013.277 . free .
  121. Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N, Lomedico A, Faraone SV, Biederman J . Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies . The Journal of Clinical Psychiatry . 74 . 9 . 902–917 . September 2013 . 24107764 . 3801446 . 10.4088/JCP.12r08287 .
  122. Frodl T, Skokauskas N . Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects . Acta Psychiatrica Scandinavica . 125 . 2 . 114–126 . February 2012 . 22118249 . 10.1111/j.1600-0447.2011.01786.x . 25954331 . free .
  123. Viggiano D, Vallone D, Sadile A . Dysfunctions in dopamine systems and ADHD: evidence from animals and modeling . Neural Plasticity . 11 . 1–2 . 97–114 . 2004 . 15303308 . 2565441 . 10.1155/NP.2004.97 . free .
  124. Web site: Focalin XR . RxList . 5 February 2020 . 6 August 2020 . https://web.archive.org/web/20200806185517/https://www.rxlist.com/focalin-xr-drug.htm#description . live .
  125. Web site: Concerta XL 18 mg – 54 mg prolonged release tablets . https://web.archive.org/web/20171017010139/http://www.medicines.org.uk/emc/medicine/8380 . 17 October 2017 . eMC.
  126. Miller GM . The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity . Journal of Neurochemistry . 116 . 2 . 164–176 . January 2011 . 21073468 . 3005101 . 10.1111/j.1471-4159.2010.07109.x .
  127. Eiden LE, Weihe E . VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse . Annals of the New York Academy of Sciences . 1216 . 1 . 86–98 . January 2011 . 21272013 . 4183197 . 10.1111/j.1749-6632.2010.05906.x . 2011NYASA1216...86E .
  128. Sulzer D, Cragg SJ, Rice ME . Striatal dopamine neurotransmission: regulation of release and uptake . Basal Ganglia . 6 . 3 . 123–148 . August 2016 . 27141430 . 4850498 . 10.1016/j.baga.2016.02.001.
  129. Liu F, Minami H, Silva RR . Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder . Neuropsychiatric Disease and Treatment . 2 . 4 . 467–473 . December 2006 . 19412495 . 2671958 . 10.2147/nedt.2006.2.4.467 . free .
  130. Markowitz JS, DeVane CL, Ramamoorthy S, Zhu HJ . The psychostimulant d-threo-(R,R)-methylphenidate binds as an agonist to the 5HT(1A) receptor . Die Pharmazie . 64 . 2 . 123–125 . February 2009 . 19322953 .
  131. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Ding YS, Logan J, Dewey SL, Hitzemann R, Lieberman J . September 1996 . Relationship between psychostimulant-induced "high" and dopamine transporter occupancy . Proceedings of the National Academy of Sciences of the United States of America . 93 . 19 . 10388–10392 . 1996PNAS...9310388V . 10.1073/pnas.93.19.10388 . 38394 . 8816810 . free.
  132. Shoptaw S, Heinzerling KG, Rotheram-Fuller E, Steward T, Wang J, Swanson AN, De La Garza R, Newton T, Ling W . August 2008 . Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence . Drug and Alcohol Dependence . 96 . 3 . 222–232 . 10.1016/j.drugalcdep.2008.03.010 . 3652530 . 18468815.
  133. Heal DJ, Gosden J, Smith SL . December 2014 . Dopamine reuptake transporter (DAT) "inverse agonism" – a novel hypothesis to explain the enigmatic pharmacology of cocaine . Neuropharmacology . 87 . 19–40 . 10.1016/j.neuropharm.2014.06.012 . 24953830 . 4660652.
  134. Volz TJ . Neuropharmacological mechanisms underlying the neuroprotective effects of methylphenidate . Current Neuropharmacology . 6 . 4 . 379–385 . December 2008 . 19587858 . 2701286 . 10.2174/157015908787386041 .
  135. Web site: Concerta . Drugs.com . 1 October 2018 . 11 March 2019 . https://web.archive.org/web/20180929171112/https://www.drugs.com/pro/concerta.html . 29 September 2018 . live .
  136. Kimko HC, Cross JT, Abernethy DR . Pharmacokinetics and clinical effectiveness of methylphenidate . Clinical Pharmacokinetics . 37 . 6 . 457–470 . December 1999 . 10628897 . 10.2165/00003088-199937060-00002 . 397390 .
  137. Chan YP, Swanson JM, Soldin SS, Thiessen JJ, Macleod SM, Logan W . Methylphenidate hydrochloride given with or before breakfast: II. Effects on plasma concentration of methylphenidate and ritalinic acid . Pediatrics . 72 . 1 . 56–59 . July 1983 . 6866592 . 10.1542/peds.72.1.56 . 28806553 . 12 December 2021 . 17 December 2021 . https://web.archive.org/web/20211217003134/https://escholarship.org/uc/item/9gv7p39v . live .
  138. Web site: Cotempla XR-ODT- methylphenidate tablet, orally disintegrating . DailyMed . 1 July 2021 . 25 May 2022 . 26 May 2022 . https://web.archive.org/web/20220526063140/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33f70f58-c871-42c8-8adb-345caeafefcd . live .
  139. Web site: Quillivant XR- methylphenidate hydrochloride suspension, extended release . DailyMed . 30 June 2021 . 26 May 2022 . 26 May 2022 . https://web.archive.org/web/20220526063140/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c2dc2109-44a6-4797-b04e-18761dd9d45a . live .
  140. Lee L, Kepple J, Wang Y, Freestone S, Bakhtiar R, Wang Y, Hossain M . Bioavailability of modified-release methylphenidate: influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce . Biopharmaceutics & Drug Disposition . 24 . 6 . 233–243 . September 2003 . 12973820 . 10.1002/bdd.358 . 29609987 .
  141. Sun Z, Murry DJ, Sanghani SP, Davis WI, Kedishvili NY, Zou Q, Hurley TD, Bosron WF . Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1 . The Journal of Pharmacology and Experimental Therapeutics . 310 . 2 . 469–476 . August 2004 . 15082749 . 10.1124/jpet.104.067116 . 24233422 .
  142. Book: Neuropathology of Drug Addictions and Substance Misuse . Preedy VR . 2016 . Academic Press . 978-0-12-800677-1 . 3: General processes and mechanisms, prescription medications, caffeine and areca, polydrug misuse, emerging addictions, and non-drug addictions . 651 . 19 December 2018 . https://web.archive.org/web/20210829151101/https://books.google.com/books?id=Yu9eBwAAQBAJ&pg=PA651 . 29 August 2021 . live.
  143. Bagot KS, Kaminer Y . April 2014 . Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: A systematic review . Addiction . 109 . 4 . 547–557 . 10.1111/add.12460 . 4471173 . 24749160.
  144. Froimowitz M, Patrick KS, Cody V . Conformational analysis of methylphenidate and its structural relationship to other dopamine reuptake blockers such as CFT . Pharmaceutical Research . 12 . 10 . 1430–1434 . October 1995 . 8584475 . 10.1023/A:1016262815984 . 26097197 .
  145. 10.1002/1615-4169(200107)343:5<379::AID-ADSC379>3.0.CO;2-4. Prashad M . 2001 . Approaches to the Preparation of Enantiomerically Pure (2R,2R)-(+)-threo-Methylphenidate Hydrochloride . Adv. Synth. Catal. . 343 . 5 . 379–392 .
  146. Book: Baselt R . 2011 . Disposition of Toxic Drugs and Chemicals in Man . 9th . Biomedical Publications . Seal Beach, CA . 1091–1093.
  147. Lange KW, Reichl S, Lange KM, Tucha L, Tucha O . December 2010 . The history of attention deficit hyperactivity disorder . Attention Deficit and Hyperactivity Disorders . 2 . 4 . 241–255 . 21258430 . 3000907 . 10.1007/s12402-010-0045-8 .
  148. Wenthur CJ . Classics in chemical neuroscience: Methylphenidate . ACS Chem Neurosci . 7 . 8 . 1030–1040 . August 2016 . 27409720 . 10.1021/acschemneuro.6b00199 .
  149. Panizzon L . La preparazione di piridile piperidil-arilacetonitrili e di alcuni prodotti di trasformazione (Parte Ia) . Helvetica Chimica Acta . 27 . 1748–1756 . 1944 . 10.1002/hlca.194402701222.
  150. Book: Myers RL . 1 January 2007 . The 100 Most Important Chemical Compounds: A reference guide . ABC-CLIO . 978-0-313-33758-1 . 178 . live . Google Books . 24 September 2016 . https://web.archive.org/web/20170202064317/https://books.google.com/books?id=a4DuGVwyN6cC&pg=PA178&lpg=PA178&dq=named+ritalin+after+his+wife#v=onepage&q=named%20ritalin%20after%20his%20wife&f=false . 2 February 2017.
  151. Heal DJ, Pierce DM . 2006 . Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system . CNS Drugs . 20 . 9 . 713–738 . 16953648 . 10.2165/00023210-200620090-00002 . 39535277.
  152. Meier R, Gross F, Tripod J . May 1954 . Ritalin, eine neuartige synthetische Verbindung mit spezifischer zentralerregender Wirkungskomponente . de . Ritalin, a new synthetic compound with specific analeptic components . Klinische Wochenschrift . 32 . 19–20 . 445–450 . 13164273 . 10.1007/BF01466968 . 24516999 .
  153. Wood S, Sage JR, Shuman T, Anagnostaras SG . 2014 . Psychostimulants and cognition: A continuum of behavioral and cognitive activation . Pharmacol Rev . 66 . 1 . 193–221 . 24344115 . 3880463 . 10.1124/pr.112.007054.
  154. US . 2507631 . Hartmann, M.; Panizzon, L. . 16 May 1950 . Pyridine and piperidine compounds and process of making same . CIBA Pharmaceutical Products, Inc.
  155. US . 2838519 . Rouietscji, R. . 10 June 1958 . Process for the conversion of stereoisomers . CIBA Pharmaceutical Products, Inc.
  156. US . 2957880 . Rouietscji, R. . 25 October 1960 . Process for the conversion of stereoisomers . CIBA Pharmaceutical Products, Inc.
  157. Book: Myers RL . August 2007 . The 100 Most Important Chemical Compounds: A reference guide . ABC-CLIO . 978-0-313-33758-1 . registration . 10 September 2010 . 178 . ... named ritalin after his wife ....
  158. Book: Stolerman I . 2010 . Encyclopedia of Psychopharmacology . Springer . Berlin, DE / London, UK . 978-3-540-68698-9 . 763.
  159. McCrossin S . 1995 . Ritalin and attention deficit disorder: History of its use, effects, and side effects . 22 July 2014 . dead . https://web.archive.org/web/20120824105824/http://www.crossinology.com/pdf/RITALINus.pdf . 24 August 2012 .
  160. Bradley C . January 1950 . Benzedrine and dexedrine in the treatment of children's behavior disorders . Pediatrics . 5 . 1 . 24–37 . 15404645 . 10.1542/peds.5.1.24 . 45655000 .
  161. Woodworth T . 16 May 2000 . DEA Congressional Testimony . . 2 November 2007 . dead . https://web.archive.org/web/20071012061712/http://www.dea.gov/pubs/cngrtest/ct051600.htm . 12 October 2007 .
  162. Web site: Drug Approval Package: Concerta (methylphenidate HCI) NDA #21-121 . 24 December 1999 . fda.gov . 26 March 2022 . live . https://web.archive.org/web/20220327053311/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-121_Concerta.cfm . 27 March 2022.
  163. Web site: Newly Approved Drug Therapies (637) Concerta, Alza . CenterWatch . dead . 30 April 2011 . https://web.archive.org/web/20101216171133/http://centerwatch.com/drug-information/fda-approvals/drug-details.aspx?DrugID=637 . 16 December 2010.
  164. Narcotics monitoring board reports 66% increase in global consumption of methylphenidate . The Pharmaceutical Journal. Royal Pharmaceutical Society . 19 December 2018 . 4 March 2015. 294. 7853. 10.1211/PJ.2015.20068042 . https://web.archive.org/web/20181219230236/https://www.pharmaceutical-journal.com/news-and-analysis/news-in-brief/narcotics-monitoring-board-reports-66-increase-in-global-consumption-of-methylphenidate/20068042.article?firstPass=false . 19 December 2018 . live .
  165. Web site: Methylphenidate - Drug Usage Statistics . ClinCalc . 14 January 2024 .
  166. Moscibrodzki P, Katz C . 8 December 2018 . Application for inclusion to the 22nd expert committee on the selection and use of essential medicines: Methylphenidate hydrochloride . . 16 November 2019 . 6 August 2020 . https://web.archive.org/web/20200806210756/https://www.who.int/selection_medicines/committees/expert/22/applications/s24_methylphenidate.pdf . live.
  167. Foquest: Methylphenidate hydrochloride controlled release capsules . Product Monograph . vers. E . 1 March 2019 . Purdue Pharma . Pickering, Ontario, Canada . caddra.ca . Submission Control Nr 214860 . 14 December 2022.
  168. Web site: Education / training . Clinical resources . Illinois DocAssist . . Chicago, IL . dead . 26 July 2012 . https://web.archive.org/web/20130101125300/http://www.psych.uic.edu/docassist/ClinicalResources.html . 1 January 2013 . Ritalin‑SR, methylphenidate SR, Methylin ER, and Metadate ER are the same formulation and have the same drug delivery system.
  169. Comparative bioavailability . Apo‑methylphenidate SR . product monograph . PDF . Apotex Inc . 26 July 2012 . 31 March 2005.
  170. New product: Sandoz methylphenidate SR 20 mg . Sandoz Canada Inc . live . 26 July 2012 . 5 May 2009 . An alternative to Ritalin‑SR from Novartis . https://web.archive.org/web/20121203062249/http://www.rxbriefcase.com/rxNow/Archive/Sandoz/506_Methylphenidate%20SR%20launch%20Fax_EN.pdf . 3 December 2012.
  171. Web site: FDA approved drug products . Drugs@FDA . . 1 October 2016 . live . https://web.archive.org/web/20161002201213/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm . 2 October 2016.
  172. Hosenbocus S, Chahal R . A review of long-acting medications for ADHD in Canada . Journal of the Canadian Academy of Child and Adolescent Psychiatry . 18 . 4 . 331–339 . November 2009 . 19881943 . 2765387 .
  173. Web site: Aptensio XR Prescribing Information . 15 April 2017 . https://web.archive.org/web/20170202000406/http://www.aptensioxr.com/resources/full-prescribing-information.pdf . 2 February 2017 . live.
  174. Web site: Moses S . 26 July 2009 . Methylphenidate . Family Practice Notebook . 7 August 2012 . live . https://web.archive.org/web/20120914020554/http://www.fpnotebook.com/Peds/Pharm/Mthylphndt.htm . 14 September 2012.
  175. Web site: Daytrana transdermal . WebMD . 11 June 2015 . https://web.archive.org/web/20150611051920/http://www.webmd.com/drugs/2/drug-144192/daytrana+transdermal/details . 11 June 2015 . live.
  176. Quillichew ER (methylphenidate HCl extended-release chewable tablets CII) . Pfizer Medical Information (pfizermedicalinformation.com) . Pfizer . U.S. . dead . 16 April 2017 . https://web.archive.org/web/20170416125833/https://www.pfizermedicalinformation.com/en-us/quillichew-er . 16 April 2017.
  177. Web site: Jornay PM Full Prescribing Information . accessdata.fda.gov . FDA . 27 April 2024.
  178. Web site: Concerta for Kids with ADHD . https://web.archive.org/web/20110107153016/http://pediatrics.about.com/cs/adhd/a/concerta.htm . 7 January 2011 . Pediatrics.about.com . 1 April 2003.
  179. Web site: Concerta (methylphenidate extended-release tablets) . Drug information: User reviews, side effects, drug interactions, and dosage . RxList . https://web.archive.org/web/20110326160650/http://www.rxlist.com/concerta-drug.htm . 26 March 2011 . 30 April 2011.
  180. Web site: Metadate CD . https://web.archive.org/web/20110710185835/http://adhd.emedtv.com/metadate-cd/metadate-cd.html . 10 July 2011 .
  181. Coghill D, Banaschewski T, Zuddas A, Pelaz A, Gagliano A, Doepfner M . Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies . BMC Psychiatry . 13 . 237 . September 2013 . 24074240 . 3852277 . 10.1186/1471-244X-13-237 . free .
  182. Web site: UK Report on Ritalin . 9 January 2024 . 9.
  183. Steingard R, Taskiran S, Connor DF, Markowitz JS, Stein MA . New Formulations of Stimulants: An Update for Clinicians . J Child Adolesc Psychopharmacol . 29 . 5 . 324–339 . June 2019 . 31038360 . 7207053 . 10.1089/cap.2019.0043 .
  184. Methylphenidate transdermal system (MTS) . 24 October 2005 . safety summary ., Appendix 3 . Noven Pharmaceuticals . . dead . 17 January 2022 . https://web.archive.org/web/20070930004912/http://www.fda.gov/ohrms/dockets/AC/05/briefing/2005-4195B1_01_04-Noven-Appendix-3.pdf . 30 September 2007.
  185. Heal DJ, Pierce DM . Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system . CNS Drugs . 20 . 9 . 713–738 . 2006 . 16953648 . 10.2165/00023210-200620090-00002 . 39535277 .

    Anderson VR, Scott LJ . Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children . Drugs . 66 . 8 . 1117–1126 . 2006 . 16789796 . 10.2165/00003495-200666080-00007 . 46975783 .

  186. Green List: Annex to the annual statistical report on psychotropic substances (form P) . August 2003 . International Narcotics Board . 23rd . . 2 March 2006 . https://web.archive.org/web/20120831222336/http://www.incb.org/pdf/e/list/green.pdf . 31 August 2012 . dead . Vienna International Centre, Austria.
  187. Web site: 27 November 2014 . Poisons Standard 2012 as amended made under paragraph 52D(2)(a) of the Therapeutic Goods Act 1989 . live . https://web.archive.org/web/20150701012941/https://www.comlaw.gov.au/Details/F2015C00043 . 1 July 2015 . 28 June 2015 . Therapeutic Goods Administration.
  188. Controlled Drugs and Substances Act . 25 April 2017 . Department of Justice, Government of Canada . S.C. 1996, c. 19 . 26 April 2017 . https://web.archive.org/web/20110403004630/http://laws-lois.justice.gc.ca/eng/acts/C-38.8/ . 3 April 2011 . live . Laws.
  189. Web site: FIJI ISLANDS ILLICIT DRUGS CONTROL ACT 2004 . dead . https://web.archive.org/web/20180713134828/http://www.health.gov.fj/wp-content/uploads/2018/02/Fiji-Illicit-Drug-Act-2004.pdf . 13 July 2018 . 5 August 2023 . health.gov.fj.
  190. News: TDAH : la prescription de méthylphénidate peut désormais être initiée en villexxxxxxxxx . VIDAL . fr.
  191. Web site: Dangerous Drugs Ordinance . live . https://web.archive.org/web/20210828171921/https://www.elegislation.gov.hk/checkconfig/success.jsp . 28 August 2021 . 20 March 2019 . Hong Kong e-Legislation . 1438402701417-001.
  192. The Drugs and Cosmetics Rules . 15 August 2013 . Government of India . 729–730 . 5 December 2016 . https://web.archive.org/web/20160808040545/http://mohfw.nic.in/showfile.php?lid=3036 . 8 August 2016 . live . 1945 . Ministry of Health & Family Welfare.
  193. Drug Law Enforcement Field Officers' Hand Book . 26 February 2014 . Government of India . 145 . 5 December 2016 . https://web.archive.org/web/20170305004634/http://narcoticsindia.nic.in/upload/download/document_idd8a4e572d866aa45da78418d9d2ff9f9.pdf . 5 March 2017 . dead . Mehta R . Narcotics Control Bureau, Ministry of Home Affairs.
  194. Web site: Decree of the Government of Russian Federation on 25 October 2014 . live . https://web.archive.org/web/20150326231624/http://government.ru/media/files/AXPVbdY3sc4.pdf . 26 March 2015 . 17 October 2019 . No. 1102.
  195. Web site: Narkotikastrafflag (1968:64) . live . https://web.archive.org/web/20131006112822/https://lagen.nu/1968:64 . 6 October 2013 . 15 January 2014 . Ministry of Justice.
  196. Misuse of Drugs Act (c. 38) . Office of Public Sector Information . 15 June 2009 . https://web.archive.org/web/20210828171920/https://www.legislation.gov.uk/ukpga/1971/38/schedule/2/2003-04-01?timeline=true . 28 August 2021 . live . 1971 . Schedule 2: Controlled Drugs . http://www.statutelaw.gov.uk/content.aspx?LegType=All+Legislation&title=The+Misuse+of+Drugs+Act+1971&searchEnacted=0&extentMatchOnly=0&confersPower=0&blanketAmendment=0&sortAlpha=0&TYPE=QS&PageNumber=1&NavFrom=0&parentActiveTextDocId=1367412&ActiveTextDocId=1367471&filesize=1699.
  197. Web site: Finlator J . 28 October 1971 . Phenmetrazine and its salts, and Methylphenidate . live . https://web.archive.org/web/20220303023153/http://isomerdesign.com/Cdsa/FR/36FR20686.pdf . 3 March 2022 . 16 January 2023 . Isomer Design . Bureau of Narcotics and Dangerous Drugs.
  198. Lakhan SE, Hagger-Johnson GE . October 2007 . The impact of prescribed psychotropics on youth . Clinical Practice and Epidemiology in Mental Health . 3 . 1 . 21 . 17949504 . 2100041 . 10.1186/1745-0179-3-21 . free .
  199. News: New research helps explain ritalin's low abuse potential when taken as prescribed . 29 September 1998 . NIH.gov . 30 April 2011 . https://web.archive.org/web/20100528060023/http://www.nih.gov/news/pr/sept98/nida-29.htm . 28 May 2010.
  200. Web site: Stimulant ADHD medications: Methylphenidate and amphetamines . NIDA InfoFacts . Drugabuse.gov . 30 April 2011 . https://web.archive.org/web/20100326223023/http://www.drugabuse.gov/infofacts/ADHD.html . 26 March 2010.
  201. Schoenfelder EN, Faraone SV, Kollins SH . June 2014 . Stimulant treatment of ADHD and cigarette smoking: A meta-analysis . Pediatrics . 133 . 6 . 1070–1080 . 24819571 . 4531271 . 10.1542/peds.2014-0179 .
  202. Wilens TE, Faraone SV, Biederman J, Gunawardene S . Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature . Pediatrics . 111 . 1 . 179–185 . January 2003 . 12509574 . 10.1542/peds.111.1.179 . 29956425 .
  203. Karlstad Ø, Zoëga H, Furu K, Bahmanyar S, Martikainen JE, Kieler H, Pottegård A . Use of drugs for ADHD among adults-a multinational study among 15.8 million adults in the Nordic countries . European Journal of Clinical Pharmacology . 72 . 12 . 1507–1514 . December 2016 . 27586399 . 5110707 . 10.1007/s00228-016-2125-y .
  204. Bjarnadottir GD, Haraldsson HM, Rafnar BO, Sigurdsson E, Steingrimsson S, Johannsson M, Bragadottir H, Magnusson A . Prevalent intravenous abuse of methylphenidate among treatment-seeking patients with substance abuse disorders: a descriptive population-based study . Journal of Addiction Medicine . 9 . 3 . 188–194 . 29 November 2016 . 25748561 . 4450903 . 10.1097/ADM.0000000000000115 .
  205. Ouellette EM . Legal issues in the treatment of children with attention deficit hyperactivity disorder . Journal of Child Neurology . 6 . Suppl . S68–S75 . 1991 . 2002217 . 10.1177/0883073891006001S08 . 1773939 .
  206. Ruthirakuhan MT, Herrmann N, Abraham EH, Chan S, Lanctôt KL . Pharmacological interventions for apathy in Alzheimer's disease . Cochrane Database Syst Rev . 5 . 5 . CD012197 . May 2018 . 29727467 . 6494556 . 10.1002/14651858.CD012197.pub2 .
  207. Lee CW, Chen JY, Ko CC, Chuang MH, Tsai WW, Sun CK, Hung KC . Efficacy of methylphenidate for the treatment of apathy in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled studies . Psychopharmacology (Berl) . 239 . 12 . 3743–3753 . December 2022 . 36243827 . 10.1007/s00213-022-06261-y .
  208. Theleritis C, Siarkos K, Katirtzoglou E, Politis A . Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease : A systematic review across modalities . Journal of Geriatric Psychiatry and Neurology . 30 . 1 . 26–49 . January 2017 . 28248559 . 10.1177/0891988716678684 . 24642197 .
  209. Spiegel DR, Warren A, Takakura W, Servidio L, Leu N . Disorders of diminished motivation: What they are, and how to treat them . Current Psychiatry . January 2018 . 17 . 1 . 10–18,20 .
  210. Arnts H, van Erp WS, Lavrijsen JC, van Gaal S, Groenewegen HJ, van den Munckhof P . On the pathophysiology and treatment of akinetic mutism . Neurosci Biobehav Rev . 112 . 270–278 . May 2020 . 32044373 . 10.1016/j.neubiorev.2020.02.006 . free . 2066/225901 . free .
  211. Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen J . Pharmacotherapy of methamphetamine addiction: an update . Substance Abuse . 29 . 3 . 31–49 . 2008 . 19042205 . 2597382 . 10.1080/08897070802218554 .
  212. Grabowski J, Roache JD, Schmitz JM, Rhoades H, Creson D, Korszun A . Replacement medication for cocaine dependence: methylphenidate . Journal of Clinical Psychopharmacology . 17 . 6 . 485–488 . December 1997 . 9408812 . 10.1097/00004714-199712000-00008 .
  213. Web site: US National Institute on Drug Addiction. 1 February 2019. 11 February 2023 . Understanding drug abuse and addiction: What science says .
  214. Shearer J . The principles of agonist pharmacotherapy for psychostimulant dependence . Drug and Alcohol Review . 27 . 3 . 301–308 . May 2008 . 18368612 . 10.1080/09595230801927372 . free .
  215. Villas-Boas CB, Chierrito D, Fernandez-Llimos F, Tonin FS, Sanches AC . Pharmacological treatment of attention-deficit hyperactivity disorder comorbid with an anxiety disorder: a systematic review . Int Clin Psychopharmacol . 34 . 2 . 57–64 . March 2019 . 30422834 . 10.1097/YIC.0000000000000243 . In a retrospective analysis of a case series, the monotherapy with extendedrelease methylphenidate was seen to be effective in reducing ADHD and social AD symptoms evaluated by the Adult ADHD Self-Report Scale (ASRS) and Liebowitz Social Anxiety Scale (LSAS) (Koyuncu et al., 2017)..
  216. Koyuncu A, İnce E, Ertekin E, Tükel R . Comorbidity in social anxiety disorder: diagnostic and therapeutic challenges . Drugs Context . 8 . 212573 . 2019 . 30988687 . 6448478 . 10.7573/dic.212573 . Attention-deficit/hyperactivity disorder (ADHD), another childhood disorder that extends over adulthood, is an overlooked condition that has high rates of comorbidity with SAD.31 Only recently increasing evidence suggests that the relationship between the two disorders is closer than that was thought before. Several studies found high rates (up to 60–70%) of childhood ADHD comorbidity, especially predominantly inattentive type, in adults with SAD.67,157,158 In addition, follow-up studies showed that the lifetime prevalence of SAD among ADHD patients is higher compared to healthy controls.159 In treatment studies investigating patients with SAD plus ADHD comorbidity found that ADHD medications such as methylphenidate or atomoxetine could effectively improve symptoms of both disorders at the same time.160–163 According to a developmental hypothesis, SAD may be etiologically linked to ADHD in a subgroup of patients, and thus SAD may develop secondary to ADHD.31.
  217. Pelissolo A, Abou Kassm S, Delhay L . Therapeutic strategies for social anxiety disorder: where are we now? . Expert Rev Neurother . 19 . 12 . 1179–1189 . December 2019 . 31502896 . 10.1080/14737175.2019.1666713 . Recently, clinical studies have found high rates of Attention-deficit/hyperactivity disorder (ADHD) in SAD children (up to 60-%), but also in adults [98]. Koyuncu et al. proposed a “developmental hypothesis”, suggesting that SAD may be etiologically linked to ADHD in a subgroup of patients. The impact of this association on response to treatment still needs investigations, but preliminary studies showed that atomoxetine and methylphenidate can be effective in treating both ADHD and comorbid SAD [99,100]..
  218. Golubchik P, Sever J, Weizman A . Methylphenidate treatment in children with attention deficit hyperactivity disorder and comorbid social phobia . Int Clin Psychopharmacol . 29 . 4 . 212–215 . July 2014 . 24448460 . 4047304 . 10.1097/YIC.0000000000000029 .
  219. Koyuncu A, Çelebi F, Ertekin E, Kahn DA . Extended-release Methylphenidate Treatment and Outcomes in Comorbid Social Anxiety Disorder and Attention-deficit/Hyperactivity Disorder: 2 Case Reports . J Psychiatr Pract . 21 . 3 . 225–231 . May 2015 . 25955266 . 10.1097/PRA.0000000000000070 .
  220. Koyuncu A, Çelebi F, Ertekin E, Kök BE, Tükel R . Extended-release methylphenidate monotherapy in patients with comorbid social anxiety disorder and adult attention-deficit/hyperactivity disorder: retrospective case series . Ther Adv Psychopharmacol . 7 . 11 . 241–247 . November 2017 . 29090087 . 5638159 . 10.1177/2045125317714193 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Methylphenidate".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.